Table 3.
Significant associations between genetic variants in circadian genes and prostate cancer risk
| All | Less Aggressive | More Aggressive | ||||||
|---|---|---|---|---|---|---|---|---|
| Genotype | Controls | Cases | OR* | Cases | OR* | Cases. | OR* | |
| N | N | (95% CI) | N | (95% CI) | N | (95% CI) | P-Value† | |
| PER1, rs885747, tag | ||||||||
| C/C | 367 | 375 | Ref. | 239 | Ref. | 136 | Ref. | |
| C/G | 615 | 639 | 1.00 (0.83–1.20) | 432 | 1.05 (0.86–1.30) | 207 | 0.90 (0.70–1.16) | 0.24 |
| G/G | 257 | 238 | 0.90 (0.72–1.14) | 170 | 1.01 (0.78–1.31) | 68 | 0.71 (0.51–0.99) | 0.05 |
| C/G+G/G | 872 | 877 | 0.97 (0.82–1.15) | 602 | 1.04 (0.86–1.27) | 275 | 0.84 (0.66–1.07) | 0.10 |
| PER1, rs2289591, tag | ||||||||
| G/G | 702 | 696 | Ref. | 487 | Ref. | 209 | Ref. | |
| G/T | 461 | 459 | 1.00 (0.84–1.18) | 296 | 0.91 (0.75–1.10) | 163 | 1.19 (0.94–1.51) | 0.04 |
| T/T | 68 | 79 | 1.24 (0.88–1.75) | 47 | 1.05 (0.71–1.55) | 32 | 1.70 (1.08–2.66) | 0.05 |
| G/T+T/T | 529 | 538 | 1.03 (0.87–1.20) | 343 | 0.93 (0.78–1.11) | 195 | 1.25 (1.00–1.57) | 0.02 |
| PER2, rs7602358, tag | ||||||||
| T/T | 706 | 669 | Ref. | 436 | Ref. | 233 | Ref. | |
| T/G | 421 | 464 | 1.15 (0.97–1.36) | 327 | 1.24 (1.03–1.50) | 137 | 0.98 (0.77–1.25) | 0.07 |
| G/G | 76 | 74 | 1.01 (0.72–1.42) | 45 | 0.94 (0.64–1.39) | 29 | 1.13 (0.72–1.79) | 0.46 |
| T/G+G/G | 497 | 538 | 1.13 (0.96–1.33) | 372 | 1.19 (1.00–1.43) | 166 | 1.00 (0.80–1.26) | 0.16 |
| PER3, rs1012477, tag | ||||||||
| C/C | 914 | 899 | Ref. | 584 | Ref. | 315 | Ref. | |
| C/G | 290 | 331 | 1.15 (0.96–1.39) | 238 | 1.28 (1.04–1.56) | 93 | 0.92 (0.71–1.21) | 0.02 |
| G/G | 31 | 27 | 0.85 (0.50–1.45) | 20 | 0.97 (0.54–1.73) | 7 | 0.63 (0.27–1.45) | 0.33 |
| C/G+G/G | 321 | 358 | 1.12 (0.94–1.34) | 258 | 1.25 (1.03–1.52) | 100 | 0.89 (0.69–1.16) | 0.02 |
| CSNK1E, rs1534891, cgems | ||||||||
| C/C | 941 | 966 | Ref. | 641 | Ref. | 325 | Ref. | |
| C/T | 292 | 266 | 0.88 (0.73–1.06) | 183 | 0.91 (0.73–1.12) | 83 | 0.82 (0.62–1.08) | 0.50 |
| T/T | 8 | 23 | 2.65 (1.16–5.95) | 18 | 3.09 (1.32–7.21) | 5 | 1.70 (0.55–5.29) | 0.25 |
| C/T+T/T | 300 | 289 | 0.93 (0.77–1.12) | 201 | 0.97 (0.79–1.19) | 88 | 0.85 (0.64–1.11) | 0.35 |
| CRY1, rs12315175, tag | ||||||||
| T/T | 805 | 778 | Ref. | 515 | Ref. | 263 | Ref. | |
| T/C | 387 | 406 | 1.09 (0.92–1.30) | 279 | 1.14 (0.94–1.38) | 127 | 1.01 (0.79–1.29) | 0.38 |
| C/C | 47 | 63 | 1.47 (0.99–2.18) | 44 | 1.55 (1.01–2.39) | 19 | 1.30 (0.75–2.26) | 0.53 |
| T/C+C/C | 434 | 469 | 1.13 (0.96–1.34) | 323 | 1.18 (0.98–1.42) | 146 | 1.04 (0.82–1.32) | 0.33 |
| CRY2, rs2292912, tag | ||||||||
| C/C | 763 | 812 | Ref. | 555 | Ref. | 257 | Ref. | |
| C/G | 414 | 392 | 0.88 (0.74–1.05) | 252 | 0.83 (0.68–1.00) | 140 | 1.00 (0.79–1.27) | 0.14 |
| G/G | 61 | 49 | 0.79 (0.54–1.17) | 34 | 0.81 (0.52–1.25) | 15 | 0.76 (0.43–1.37) | 0.86 |
| C/G+G/G | 475 | 441 | 0.87 (0.74–1.03) | 286 | 0.82 (0.69–0.99) | 155 | 0.97 (0.77–1.22) | 0.19 |
| ARNTL, rs7950226, tag | ||||||||
| G/G | 367 | 317 | Ref. | 213 | Ref. | 104 | Ref. | |
| G/A | 588 | 631 | 1.22 (1.01–1.48) | 430 | 1.24 (1.01–1.54) | 201 | 1.19 (0.90–1.56) | 0.76 |
| A/A | 262 | 276 | 1.22 (0.97–1.53) | 177 | 1.16 (0.90–1.51) | 99 | 1.33 (0.97–1.83) | 0.44 |
| G/A+A/A | 850 | 907 | 1.22 (1.02–1.46) | 607 | 1.22 (1.00–1.49) | 300 | 1.23 (0.95–1.59) | 0.94 |
| CLOCK, rs11133373, tag | ||||||||
| C/C | 520 | 575 | Ref. | 377 | Ref. | 198 | Ref. | |
| C/G | 571 | 533 | 0.85 (0.72–1.01) | 353 | 0.86 (0.71–1.04) | 180 | 0.82 (0.65–1.04) | 0.71 |
| G/G | 131 | 134 | 0.91 (0.69–1.19) | 102 | 1.06 (0.79–1.42) | 32 | 0.62 (0.41–0.95) | 0.02 |
| C/G+G/G | 702 | 667 | 0.86 (0.73–1.01) | 455 | 0.90 (0.75–1.08) | 212 | 0.79 (0.63–0.99) | 0.26 |
| NPAS2, rs1369481, tag | ||||||||
| G/G | 600 | 677 | Ref. | 456 | Ref. | 221 | Ref. | |
| G/A | 535 | 484 | 0.81 (0.68–0.96) | 326 | 0.81 (0.67–0.98) | 158 | 0.80 (0.63–1.02) | 0.95 |
| A/A | 104 | 93 | 0.80 (0.59–1.09) | 60 | 0.77 (0.55–1.09) | 33 | 0.86 (0.57–1.32) | 0.62 |
| G/A+A/A | 639 | 577 | 0.81 (0.69–0.95) | 386 | 0.80 (0.67–0.96) | 191 | 0.81 (0.65–1.02) | 0.92 |
| NPAS2, rs895521, cgems | ||||||||
| G/G | 709 | 778 | Ref. | 519 | Ref. | 259 | Ref. | |
| G/A | 466 | 423 | 0.85 (0.71–1.0) | 291 | 0.87 (0.73–1.05) | 132 | 0.79 (0.62–1.00) | 0.42 |
| A/A | 64 | 50 | 0.71 (0.48–1.05) | 32 | 0.68 (0.44–1.06) | 18 | 0.77 (0.44–1.32) | 0.70 |
| G/A+A/A | 530 | 473 | 0.83 (0.70–0.97) | 323 | 0.85 (0.71–1.02) | 150 | 0.79 (0.62–0.99) | 0.52 |
| NPAS2, rs17024926, tag | ||||||||
| T/T | 563 | 499 | Ref. | 330 | Ref. | 169 | Ref. | |
| T/C | 536 | 594 | 1.26 (1.06–1.49) | 394 | 1.26 (1.04–1.53) | 200 | 1.25 (0.99–1.59) | 0.95 |
| C/C | 139 | 153 | 1.23 (0.94–1.60) | 111 | 1.34 (1.00–1.78) | 42 | 1.01 (0.68–1.49) | 0.17 |
| T/C+C/C | 675 | 747 | 1.25 (1.07–1.47) | 505 | 1.28 (1.07–1.53) | 242 | 1.20 (0.96–1.51) | 0.62 |
*
Adjusted for age and family history of prostate cancer in a first-degree relative
†
Test for homogeneity of ORs for less versus more aggressive disease groups